OTX-BPI

OTX-BPI is an investigational **sustained-release intracanalicular hydrogel insert** developed by **Ocular Therapeutix** for the treatment of **acute ocular pain**. Preclinical disclosures describe it as a hydrogel matrix containing **bupivacaine particles** that is inserted into the lid punctum and designed to provide prolonged local anesthetic exposure at the ocular surface. Its intended pharmacology is inhibition of **voltage-gated sodium channels** by bupivacaine, thereby reducing nerve conduction and ocular pain signaling. Publicly available information appears limited to preclinical presentations, and no clear evidence of later-stage clinical development or marketing was identified.

Other names

bupivacaine intracanalicular hydrogel insertsustained release bupivacaine intracanalicular hydrogel insert